Lowering the Repeat Unplanned Revascularization Rate After Coronary Stenting by Focusing on the Long-Term Stable Control of Low-Density Lipoprotein Cholesterol
Coronary artery disease (CAD) remains a significant global health burden, and percutaneous coronary intervention (PCI) with stent implantation is a cornerstone in its management. However, despite the initial success of PCI, a substantial proportion of patients require repeat unplanned revascularization due to plaque progression in culprit or non-culprit lesions. These revascularization procedures include target lesion revascularization (TLR), target vessel revascularization (TVR), and other vessel revascularization (OVR). Low-density lipoprotein cholesterol (LDL-C) is a well-established modifiable risk factor in cardiovascular disease, and its reduction is critical in preventing major adverse cardiac events (MACE) after PCI. This study investigates the role of long-term stable control of LDL-C in reducing the rate of repeat unplanned revascularization after coronary stenting.
The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Affiliated Hospital of Dalian Medical University. It included 621 consecutive patients who underwent successful PCI with stent implantation between January 2013 and January 2017. These patients were readmitted for a second coronary angiography due to suspected or defined myocardial ischemia. Patients who underwent staged revascularization within six months of discharge were excluded, leaving 510 patients for analysis. The cohort was divided into two groups: 101 patients without de novo coronary artery lesions (control group) and 409 patients who underwent repeat unplanned percutaneous revascularization (repeat PCI group). Among the repeat PCI group, 10% were treated for ST-elevation myocardial infarction (STEMI), while 90% were treated for non-ST-segment elevation acute coronary syndromes (NSTE-ACS). Within this group, 183 patients underwent TLR, 272 underwent TVR/OVR, and 46 underwent both procedures.
Statistical analyses were performed using SPSS 21.0. Continuous data were presented as mean ± standard deviation, and categorical data were described using medians and interquartile ranges. Comparisons between groups were made using t-tests for continuous data and chi-squared tests for categorical data. Multivariate Cox regression analyses were conducted to adjust for demographic, clinical, and procedural variables. Risk ratios and 95% confidence intervals (CIs) were calculated, with a p-value of less than 0.05 considered statistically significant.
Baseline characteristics, including LDL-C levels, were well-balanced between the control and repeat PCI groups at the time of the first PCI. However, the interval time between the first PCI and readmission was significantly shorter in the control group (2.0 ± 1.4 years) compared to the repeat PCI group (4.1 ± 3.3 years, p < 0.001). Initial reductions in LDL-C levels were observed in both groups, with the control group showing a decrease from 108.04 ± 30.77 mg/dL to 87.93 ± 25.62 mg/dL. In contrast, the repeat PCI group demonstrated a less pronounced reduction, with LDL-C levels decreasing from 108.83 ± 30.05 mg/dL to 96.07 ± 29.10 mg/dL. This attenuation of LDL-C control over time was associated with a higher risk of repeat unplanned revascularization. Patients in the repeat PCI group had significantly higher LDL-C levels at readmission compared to the control group (p = 0.006). Additionally, the proportion of patients with LDL-C levels ≥100 mg/dL was higher in the repeat PCI group (37.4% vs. 25.7%, p = 0.02).
Multivariate Cox regression analysis revealed that LDL-C levels ≥100 mg/dL during readmission were an independent risk factor for all repeat unplanned PCI procedures, as well as for TLR and TVR/OVR individually. These findings underscore the importance of maintaining long-term stable control of LDL-C levels in patients with CAD after PCI. Despite initial reductions in LDL-C levels, the study highlights the tendency for lipid-lowering therapy to lose emphasis over time, leading to suboptimal LDL-C control and increased risk of revascularization.
The study also observed that more than 20% of patients with CAD continue to experience atheroma progression even after achieving very low LDL-C levels. Current lipid-lowering guidelines emphasize LDL-C reduction as a primary target for both primary and secondary prevention of cardiovascular disease, particularly in patients who have undergone PCI. However, in clinical practice, the focus on active lipid-lowering therapy with statins often diminishes after the first year post-PCI. This is reflected in the increasing number of patients on low statin doses or without statin therapy over time. The study further noted changes in the types of statins used, although it did not explore the specific impact of these changes on outcomes.
Several limitations of the study should be acknowledged. First, it was a single-center, retrospective analysis, which may limit the generalizability of the findings. The study population was restricted to patients with successful follow-up and repeat angioplasty, potentially introducing selection bias. Additionally, the interval times between the first PCI and readmission differed between the control and repeat PCI groups, which could have influenced the results. To address this, interval time was included as a survival time variable in the multivariate Cox regression analysis. The study also excluded patients who underwent repeat unplanned revascularization via coronary artery bypass grafting, which may have affected the final outcomes. Finally, the study did not investigate the specific types of lipid-lowering drugs or other variables that could influence lesion progression and PCI outcomes, potentially impacting the results.
In conclusion, this study highlights the critical role of long-term stable control of LDL-C levels in reducing the rate of repeat unplanned revascularization after coronary stenting. Despite initial reductions in LDL-C levels, the attenuation of lipid-lowering therapy over time leads to suboptimal control and increased risk of revascularization. These findings emphasize the need for sustained emphasis on lipid-lowering therapy in patients with CAD after PCI to achieve better long-term outcomes. Future research should explore the impact of specific lipid-lowering drugs and other factors on lesion progression and PCI outcomes to further optimize management strategies.
doi.org/10.1097/CM9.0000000000000373
Was this helpful?
0 / 0